AstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In Trial
17 Maio 2023 - 4:21AM
Dow Jones News
By Christian Moess Laursen
AstraZeneca said Wednesday that trial results showed that its
Tagrisso drug in combination with chemotherapy demonstrated strong
improvement for patients with lung cancer
The Anglo-Swedish pharmaceutical company said the FLAURA2 Phase
3 trial was for progression-free survival--the length of time a
patient lives with a disease without it getting worse--for patients
with epidermal growth factor receptor-mutated, non-small cell lung
cancer.
For the moment, the overall survival data--the length of time
from the start of diagnosis or treatment that the patient is still
alive--were still immature and will be formally assessed at a
subsequent analysis, AstraZeneca said.
"These significant FLAURA2 results show Tagrisso has the
potential to offer patients in the first-line setting a new
treatment option that can extend the time they live without their
disease progressing," Executive Vice President of the company's
Oncology R&D Susan Galbraith said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
May 17, 2023 03:06 ET (07:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
